Research & Development
Rezolute's ersodetug meets primary endpoint in Phase 3 upLIFT study of tumour hyperinsulinism
13 November 2026 - Rezolute, Inc. (NASDAQ: RZLT), a late-stage metabolic disease company focused on treating refractory hypoglycemia caused by hyperinsulinism, said preliminary results from a data eva...
Sunnyside adds GLP-1 options to its medication program for Alcohol Use Disorder
13 November 2026 - Sunnyside, a US-based Alcohol Use Disorder (AUD) treatment and prevention company, announced on Thursday the launch of two new programs that pair semaglutide, a GLP-1 medication, wi...
FDA grants Breakthrough Therapy designation to Clarity Pharmaceuticals' prostate cancer imaging agent
12 November 2026 - Australian clinical-stage radiopharmaceutical company Clarity Pharmaceuticals Ltd (ASX: CU6) said on Thursday the US Food and Drug Administration (FDA) has granted Breakthrough Ther...
Traws Pharma reports final Phase 2a COVID-19 data and advances influenza programme
12 November 2026 - Clinical-stage biopharmaceutical company Traws Pharma, Inc. (NASDAQ: TRAW) on Thursday reported final results from a 92-patient Phase 2a study of ratutrelvir, its investigational on...
Shanton Pharma's SAP-001 receives EMA and FDA paediatric study waivers in hyperuricaemia
12 November 2026 - Shanton Pharma, a China-based, clinical-stage biotech developing a novel treatment for hyperuricaemia and gout in adults, announced on Wednesday that it has reached an agreement wit...
MellingMedical partners with CellTivity Scientific to enhance diagnostic cancer sampling for federal healthcare providers
12 November 2026 - MellingMedical, a US-based company that provides veterans with access to healthcare, announced on Wednesday a new strategic relationship with CellTivity Scientific, a US-based compa...